SCOPUS 정보 검색 플랫폼

Drug Discovery Today

Volumn 16, Issue 19-20, 2011, Pages 878-883

The biomarker is not the end

(1) Nohaile, Michael a

a NOVARTIS PHARMA AG (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; PHARMACOLOGICAL BIOMARKER; TRASTUZUMAB;

CLINICAL LABORATORY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CROHN DISEASE; DIAGNOSTIC TEST; DRUG DESIGN; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; INSTRUMENT VALIDATION; PHARMACOGENOMICS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DRUG APPROVAL; DRUG DISCOVERY; GOVERNMENT REGULATION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACOGENETICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80054004797 PISSN: 13596446 EISSN: 18785832 Source Type: Journal
DOI: 10.1016/j.drudis.2011.08.011 Document Type: Review

Times cited : (8)

References (12)

1
- 67449103274
- Common sense approaches to urinary biomarker study design
- M.A. Knepper Common sense approaches to urinary biomarker study design J. Am. Soc. Nephrol. 20 2009 1175 1178
- (2009) J. Am. Soc. Nephrol. , vol.20 , pp. 1175-1178
- Knepper, M.A.¹

2
- 33745480519
- Translating genomic biomarkers into clinically useful diagnostics
- DOI 10.1586/14737159.6.2.179
- G.S. Ginsburg, and S.B. Haga Translating genomic biomarkers into clinically useful diagnostics Expert Rev. Mol. Diagn. 6 2006 179 191 (Pubitemid 44167147)
- (2006) Expert Review of Molecular Diagnostics , vol.6 , Issue.2 , pp. 179-191
- Ginsburg, G.S.¹ Haga, S.B.²

3
- 79955769226
- PriceWaterhouseCoopers
- PriceWaterhouseCoopers Diagnostics 2009. Moving towards personalised medicine 2009 PriceWaterhouseCoopers
- (2009) Diagnostics 2009. Moving Towards Personalised Medicine

4
- 1542333321
- FDA
- FDA Guidance for industry: pharmacogenomic data submissions 2005 FDA
- (2005) Guidance for Industry: Pharmacogenomic Data Submissions

5
- 20344397006
- FDA (draft)
- FDA Drug-diagnostic co-development concept paper 2005 FDA (draft)
- (2005) Drug-diagnostic Co-development Concept Paper

6
- 77956353475
- Getting the details right: Gene signatures for cancer therapy
- S.R. Master Getting the details right: gene signatures for cancer therapy Clin. Chem. 56 2010 1378 1380
- (2010) Clin. Chem. , vol.56 , pp. 1378-1380
- Master, S.R.¹

7
- 80053975973
- FDA sends a message
- M. Flanagan FDA sends a message BioCentury: The Bernstein Report on Biobusiness 2010 A15
- (2010) BioCentury: The Bernstein Report on Biobusiness , pp. 15
- Flanagan, M.¹

8
- 77954239263
- Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives
- H. Hampel Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat. Rev. Drug Discov. 9 2010 560 574
- (2010) Nat. Rev. Drug Discov. , vol.9 , pp. 560-574
- Hampel, H.¹

9
- 77954241944
- Integrating molecular diagnostics into anticancer drug discovery
- I. Peták Integrating molecular diagnostics into anticancer drug discovery Nat. Rev. Drug Discov. 9 2010 523 535
- (2010) Nat. Rev. Drug Discov. , vol.9 , pp. 523-535
- Peták, I.¹

10
- 80053939418
- FDA
- FDA Draft guidance for industry and food and drug administration staff. In vitro companion diagnostic devices 2011 FDA
- (2011) Draft Guidance for Industry and Food and Drug Administration Staff. in Vitro Companion Diagnostic Devices

11
- 84881127070
- Evolving FDA regulation and issues for resolution
- S.D. Danzis, E.J. Flannery, The Food and Drug Law Institute
- K.H. Carver Evolving FDA regulation and issues for resolution S.D. Danzis, E.J. Flannery, In vitro diagnostics: the complete regulatory guide 2010 The Food and Drug Law Institute
- (2010) In Vitro Diagnostics: The Complete Regulatory Guide
- Carver, K.H.¹

12
- 79952015320
- US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics
- R. Philip US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics Bioanalysis 3 2011 383 389
- (2011) Bioanalysis , vol.3 , pp. 383-389
- Philip, R.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.